ClinicalTrialsFinder
RecruitingNCT06708130

Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study

Sponsor

Ruijin Hospital

Enrollment

3,000 participants

Start Date

May 1, 2021

Study Type

OBSERVATIONAL

Conditions

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Summary

Clinical observational studies using epidemiologic theories and methods. Through the collection of various clinically relevant data, specific outcomes are evaluated in hematologic transplant patients, providing high quality real-world data for clinical practice, informing public health decision-making, and reducing the burden of disease

Eligibility

Inclusion Criteria2

  • At least one visit to a stem cell transplant center beginning January 1, 2021
  • Proposed to undergo or have undergone hematopoietic stem cell transplantation

Exclusion Criteria3

  • Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion
  • Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study
  • Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Shanghai Liquan Hospital

Shanghai, China

Shanghai Zhaxin Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06708130

Related Trials

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

NCT033781021 location

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT075726691 location

Nutrition OUtReach In Systems of Healthcare

NCT068024064 locations

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT0739648018 locations

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

NCT060288281 location